- Home
- CSTL vs TATT Comparison
CSTL vs TATT Comparison
Compare CSTL & TATT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- TATT
- Stock Information
- Founded
- CSTL 2007
- TATT 1985
- Country
- CSTL United States
- TATT Israel
- Employees
- CSTL N/A
- TATT N/A
- Industry
- CSTL Medical Specialities
- TATT Aerospace
- Sector
- CSTL Health Care
- TATT Industrials
- Exchange
- CSTL Nasdaq
- TATT Nasdaq
- Market Cap
- CSTL 456.2M
- TATT 379.0M
- IPO Year
- CSTL 2019
- TATT 1987
- Fundamental
- Price
- CSTL $19.46
- TATT $31.85
- Analyst Decision
- CSTL Strong Buy
- TATT Strong Buy
- Analyst Count
- CSTL 6
- TATT 3
- Target Price
- CSTL $37.67
- TATT $36.00
- AVG Volume (30 Days)
- CSTL 462.3K
- TATT 225.9K
- Earning Date
- CSTL 08-04-2025
- TATT 08-27-2025
- Dividend Yield
- CSTL N/A
- TATT N/A
- EPS Growth
- CSTL N/A
- TATT 81.73
- EPS
- CSTL N/A
- TATT 1.14
- Revenue
- CSTL $347,083,000.00
- TATT $160,170,000.00
- Revenue This Year
- CSTL N/A
- TATT $18.62
- Revenue Next Year
- CSTL $1.36
- TATT $10.62
- P/E Ratio
- CSTL N/A
- TATT $27.20
- Revenue Growth
- CSTL 38.43
- TATT 30.57
- 52 Week Low
- CSTL $15.45
- TATT $12.61
- 52 Week High
- CSTL $35.84
- TATT $36.49
- Technical
- Relative Strength Index (RSI)
- CSTL 55.41
- TATT 65.68
- Support Level
- CSTL $18.18
- TATT $29.22
- Resistance Level
- CSTL $20.63
- TATT $31.82
- Average True Range (ATR)
- CSTL 0.77
- TATT 1.40
- MACD
- CSTL 0.07
- TATT 0.57
- Stochastic Oscillator
- CSTL 57.36
- TATT 99.84
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About TATT TAT Technologies Ltd.
TAT Technologies Ltd provides solutions and services to the commercial and military aerospace and ground defense industries, focused mainly on three product areas and services: Thermal Management, Power and Actuation, and Maintenance, Repair and Overhaul (MRO). Its product portfolio includes heat exchangers, cooling systems, and mechanical aircraft accessories and systems such as pumps, valves, and turbine power units. Its operating segments are MRO services for aviation components, which derive key revenue, Original equipment manufacturing (OEM) of heat transfer solutions and aviation accessories, MRO services for heat transfer components and OEM of heat transfer solutions, and Overhaul and coating of jet engine components. Geographically, it derives key revenue from the United States.